Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia

Autor: Bäumer, Nicole, Scheller, Annika, Wittmann, Lisa, Faust, Andreas, Apel, Mara, Nimmagadda, Subbaiah Chary, Geyer, Christiane, Grunert, Katharina, Kellmann, Neele, Peipp, Matthias, Kailayangiri, Sareetha, Gutierrez Suburu, Matias Ezequiel, Strassert, Cristian A., Schenk, Mathias, Greune, Lilo, Rüter, Christian, Dersch, Petra, Hartmann, Wolfgang, Rossig, Claudia, Neri, Dario

Publikováno v: Journal of Hematology & Oncology, 15 (1)

BACKGROUND: Acute myeloid leukemia (AML) is a fatal clonal hematopoietic malignancy, which results from the accumulation of several genetic aberrations in myeloid progenitor cells, with a worldwide 5-year survival prognosis of about 30%. Therefore, t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8db584d85554ad22854e2f102541df46
https://hdl.handle.net/20.500.11850/586190

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia.

Autor: Bäumer N; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Scheller A; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Wittmann L; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Faust A; European Institute for Molecular Imaging, University of Münster, Waldeyerstr. 15, 48159, Münster, Germany., Apel M; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Nimmagadda SC; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Geyer C; Institute for Clinical Radiology, University Hospital Münster, Albert-Schweitzer Campus 1, 48149, Münster, Germany., Grunert K; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Kellmann N; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Peipp M; Division of Antibody-Based Immunotherapy, Christian-Albrechts-University, Arnold-Heller-Straße 3, 24105, Kiel, Germany., Kailayangiri S; Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Gutierrez Suburu ME; Department of Inorganic and Analytical Chemistry, University of Muenster, Corrensstraße 28/30, 48149, Münster, Germany., Strassert CA; Department of Inorganic and Analytical Chemistry, University of Muenster, Corrensstraße 28/30, 48149, Münster, Germany., Schenk M; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology IZI, Weinbergweg 22, 06120, Halle (Saale), Germany., Greune L; Institute for Infectiology, Center for Molecular Biology of Inflammation (ZMBE), University of Münster, Von-Esmarch-Str. 56, 48149, Münster, Germany., Rüter C; Institute for Infectiology, Center for Molecular Biology of Inflammation (ZMBE), University of Münster, Von-Esmarch-Str. 56, 48149, Münster, Germany., Dersch P; Institute for Infectiology, Center for Molecular Biology of Inflammation (ZMBE), University of Münster, Von-Esmarch-Str. 56, 48149, Münster, Germany., Hartmann W; Gerhard-Domagk Institute for Pathology, University of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Rossig C; Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Neri D; Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, 8093, Zurich, Switzerland., Müller-Tidow C; Department of Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany., Schwöppe C; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Schliemann C; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Khandanpour C; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Lenz G; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Berdel WE; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany., Bäumer S; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany. baumers@uni-muenster.de.

Publikováno v: Journal of hematology & oncology [J Hematol Oncol] 2022 Dec 01; Vol. 15 (1), pp. 171. Date of Electronic Publication: 2022 Dec 01.